• Головна

1.1.1 Bladder Cancer
1.1.2 Erectile Dysfunction
1.1.3 Prostate Cancer
1.1.4 Urinary Incontinence

1.2.1 Bladder, Ureteral, and Urethral Repair
1.2.2 Incontinence Treatment
1.2.3 Penile Prostheses
1.2.4 Vesicoureteral Reflux Treatment

2.1.1 Synthetic Biomaterials
2.1.2 Biologically Derived Biomaterials

2.1.2.1 Collagen
2.1.2.2 Xenogeneic Tissue

2.1.3 Hybrid Biomaterials
2.1.4 Genetically Engineered Biomaterials

2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
2.1.4.2 Genetically Manipulated Cells
2.1.4.3 Three-Dimensional Polymer Technology
2.1.4.4 Transgenics
2.1.4.5 Fibroblasts
2.1.4.6 Immortalized Neural Stem Cells
2.1.4.7 Gene-Activated Matrices

2.1.5 Scaffolds
2.1.6 Vascular Grafts

2.2.1 Bioreactors

2.2.1.1 Flatbed Perfusion Systems
2.2.1.2 Hollow Fiber Bioreactor Systems
2.2.1.3 Cell Suspension Systems
2.2.1.4 Disposable Bioreactors

2.3.1 Cell Extraction and Expansion
2.3.2 Bioreactors

2.4.1 Chimeric Immunity
2.4.2 Cell Encapsulation Technology

3.2.1 Tengion

3.3.1 Ion Channel Innovations

3.5.1 C.R. Bard
3.5.2 Boston Scientific
3.5.3 Cook Biotech/Cook Group
3.5.4 Innovacell Biotechnologie
3.5.5 Tengion

3.6.1 C.R. Bard
3.6.2 Boston Scientific
3.6.3 Oceana Therapeutics
3.6.4 Uroplasty

3.7.1 Market Drivers
3.7.2 Market Limiters